Can a lower dose of Alzheimer's drug work just as well?
NCT ID NCT07505095
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether a lower dose of the drug lecanemab works as well as the standard dose for people with early Alzheimer's disease. Researchers will compare brain scans, memory tests, and blood markers in 140 participants over 18 months. The goal is to find the most effective dose with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lecanemab
What this could lead to
If successful, this could show that a lower dose of lecanemab is just as effective, potentially reducing side effects and treatment costs for early Alzheimer's patients.
What could go wrong
This is a small, early-stage study (140 people) comparing doses, not a large trial. The lower dose may prove less effective, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Human Subject Research Ethics Committee, 2ndAffiliated Hospital, School of Medicine, Zhejiang University,
Hangzhou, Zhejiang, China